(Q36565024)

15 August 2017

1 reference

title

Safety of neuraminidase inhibitors for influenza (English)

1 reference

15 August 2017

Mark Jones

1

1 reference

15 August 2017

Chis Del Mar

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Drug Safety

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

603-608

1 reference

Antivirals for influenza in healthy adults: systematic review.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.603

21 January 2018

Identifiers

DOI

10.1517/14740338.5.5.603

1 reference

15 August 2017

1 reference